更新于：2024-11-01
Pramlintide Acetate
醋酸普兰林肽
更新于：2024-11-01
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
序列信息
Sequence Code 39914
来源: *****
关联
47
项与 醋酸普兰林肽 相关的临床试验The Impact of Pramlintide on Top of Semaglutide in Obese People With Prediabetes
The Role of Amylin in Bone Metabolism
A Randomized, Controlled, Crossover Trial to Assess a Fully Automated, Dual-hormone (Insulin-and-pramlintide) Delivery System Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 Diabetes.
100 项与 醋酸普兰林肽 相关的临床结果
登录后查看更多信息
100 项与 醋酸普兰林肽 相关的转化医学
登录后查看更多信息
100 项与 醋酸普兰林肽 相关的专利（医药）
登录后查看更多信息
388
项与 醋酸普兰林肽 相关的文献（医药）2024-11-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions improves cognitive impairments in a mouse model of Alzheimer's disease
Article
作者: Lemos-Senna, Elenara ; França, Angela P ; Zuglianello, Carine ; França, Angela P. ; Prediger, Rui D. ; Agnes, Jonathan P. ; de Souza, Bruna S. ; Prediger, Rui D ; de Souza, Bruna S ; Agnes, Jonathan P
Nasal delivery has emerged as a non-invasive route to administer drugs for brain delivery. In particular, polyelectrolyte complexes-based nanocarriers have been demonstrated to be advantageous for nasal delivery of peptide drugs and vaccines. Pramlintide (Pram) is a peptide that emerges as a novel neuroprotective strategy to modify the pathogenesis of Alzheimer's disease (AD). In this study, we examined the effects of the intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions (PEC-NEDexS/Pram) in an experimental model of AD induced by intracerebroventricular (i.c.v.) infusion of amyloid-beta (Aβ1-42) peptide in mice. PEC-NEDexS/Pram displayed droplet size lower than 200 nm and a negatively charged surface. The locomotor activity of the animals was not affected by the i.c.v. Aβ1-42 injection or Pram treatment. On the other hand, the intranasal administration of PEC-NEDexS/Pram at a dose of 100 μg/day for 14 consecutive days restored the impairment induced by Aβ1-42 injection in the discriminative learning and the short-term spatial reference memory of mice. However, Pram treatment did not alter the Aβ1-42-induced anhedonic behavior, oxidative stress parameters, or the pre-synaptic SNAP-25 and post-synaptic PSD-95 levels in the hippocampus and prefrontal cortex. These findings indicate cognitive-enhancing properties of intranasal Pram administration in an animal model of AD.
2024-10-02Expert Review of Clinical Pharmacology
Amylin analogs for the treatment of obesity without diabetes: present and future
Review
作者: Papanas, Nikolaos ; Popovic, Djordje S. ; Gouveri, Evanthia ; Panou, Theodoros
INTRODUCTION:
Obesity is a pandemic, linked with increased morbidity including diabetes mellitus (DM) and certain cancer types. Amylin is a major regulatory hormone for satiation and food intake perception in humans. Amylin analogs (pramlintide and cagrilintide) are emerging as promising anti-obesity agents in non-DM subjects.
AREAS COVERED:
Pramlintide, the first amylin analog, initially used for the treatment of both type 1 and type 2 DM, has demonstrated weight-lowering action. Clinical trials confirmed a weight loss exceeding 3% in the study period without major untoward effects, which was maintained beyond the follow-up period. Recently, cagrilintide, a long-lasting synthetic amylin analog has been introduced. Cagrilintide has achieved adequate weight loss, reaching even more than 10% of the total weight in early clinical trials. However, adverse gastrointestinal effects, particularly nausea, were more frequent compared with pramlintide. Clinical trials have also confirmed the effectiveness of cagrilintide in comparison with glucagon-like peptide 1 receptor agonists.
EXPERT OPINION:
Amylin analogs will certainly enrich the growing therapeutic armamentarium aimed at tackling obesity. The most exciting future research venue could be the development of their combinations with other weight-lowering drugs, especially dual and triple incretin-based co-agonists, thus potentially providing massive weight-loss effects.
2024-10-01DIABETES OBESITY & METABOLISM
ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes
Article
作者: Chan, You‐Ping ; DeVries, J. Hans ; Gaudier, Martin ; Heise, Tim ; Seroussi, Cyril ; Eloy, Rosy ; Andersen, Grit ; Riddle, Matthew ; Mégret, Claire ; Soula, Olivier
Abstract:
Aim:
To study safety, efficacy and weight loss with ADO09, a co‐formulation of insulin A21G and pramlintide, in type 1 diabetes.
Materials and Methods:
A randomized, two‐arm ambulatory 16‐week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes. We compared changes of weight, glycated haemoglobin, glycaemic patterns during continuous glucose monitoring, and insulin doses at baseline and at the end of treatment.
Results:
A significant and continuing weight loss, the primary endpoint, was observed with ADO09 compared with lispro as prandial insulin. In the whole group, the weight loss with ADO09 relative to lispro was 2.1 kg. Glycaemic control was relatively good (7.7% mean glycated haemoglobin) in both groups and did not change during treatment. Prandial insulin doses were reduced by 21% in the ADO09 group, whereas basal insulin dosage was not modified. Gastrointestinal symptoms were more frequent with ADO09, but no clear difference in hypoglycaemia was observed.
Conclusions:
These results extend previous observations on the efficacy and safety of this insulin/pramlintide co‐formulation. They show a beneficial effect on weight, using less mealtime insulin and without increased hypoglycaemia.
23
项与 醋酸普兰林肽 相关的新闻（医药）2024-07-14
上市批准生物类似药
2024-04-17
2024-02-23
放射疗法并购
100 项与 醋酸普兰林肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 1型糖尿病 | 美国 | 2005-03-16 | |
| 2型糖尿病 | 美国 | 2005-03-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胰岛素依赖型糖尿病2 | 临床3期 | 美国 | 2003-04-01 | |
| 肥胖 | 临床2期 | 美国 | 2004-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 觸製顧壓觸築積餘壓艱(遞繭淵壓膚壓顧壓壓醖) = 鏇襯遞蓋窪齋築艱糧網 襯獵夢醖鹽衊範餘顧選 (壓範構觸鏇遞襯壓繭襯 ) 更多 | - | 2023-01-12 | |||
觸製顧壓觸築積餘壓艱(遞繭淵壓膚壓顧壓壓醖) = 壓膚構鑰鬱獵憲艱繭醖 襯獵夢醖鹽衊範餘顧選 (壓範構觸鏇遞襯壓繭襯 ) 更多 | |||||||
临床4期 | 22 | (Baseline (Prior to Pramlintide Treatment) Mixed Meal #1) | 鏇廠衊網艱積選遞窪鏇(鬱廠網壓餘願鏇顧繭顧) = 壓積鑰鹹獵齋願鬱遞醖 壓憲鬱範觸糧窪構獵築 (醖衊艱齋獵窪夢鹽醖窪, 願製淵獵鹽簾糧齋衊艱 ~ 壓廠醖鏇鹽鹹蓋衊襯廠) 更多 | - | 2022-05-26 | ||
(Pramlintide - Mixed Meal #2) | 鏇廠衊網艱積選遞窪鏇(鬱廠網壓餘願鏇顧繭顧) = 觸願廠齋簾鏇選築蓋選 壓憲鬱範觸糧窪構獵築 (醖衊艱齋獵窪夢鹽醖窪, 觸積簾憲遞齋鏇遞築鏇 ~ 製憲夢顧艱襯夢獵觸膚) 更多 | ||||||
临床4期 | 33 | (Pramlintide) | 淵醖鏇膚範鬱鹽鹹窪願(構醖鏇醖膚觸襯鏇襯壓) = 衊壓繭醖鹹餘範衊製餘 繭鹽鹹選淵簾淵鹹壓獵 (夢醖遞製顧築淵鑰艱顧, 願壓選範憲鏇獵廠夢構 ~ 鬱餘蓋鹽鹽鏇膚鹹製願) 更多 | - | 2018-11-16 | ||
Placebo (Placebo) | 淵醖鏇膚範鬱鹽鹹窪願(構醖鏇醖膚觸襯鏇襯壓) = 蓋顧壓憲網醖觸鑰鑰衊 繭鹽鹹選淵簾淵鹹壓獵 (夢醖遞製顧築淵鑰艱顧, 糧艱鹹積製簾願淵艱窪 ~ 獵蓋艱艱構糧廠獵願網) 更多 | ||||||
临床1期 | 34 | Insulin (Placebo & Regular Insulin) | 衊鏇膚簾範鑰夢鬱糧獵(齋築蓋醖憲鑰觸鹹獵憲) = 鏇獵繭鏇廠網鑰鏇範鹽 鏇壓壓衊襯膚鑰壓觸繭 (構廠築鏇鹽膚鹽觸鑰顧, 繭鬱製鑰糧鹹觸憲積膚 ~ 願構廠憲餘鹹廠窪遞衊) 更多 | - | 2018-11-02 | ||
Insulin+Pramlintide (Pramlintide & Regular Insulin) | 衊鏇膚簾範鑰夢鬱糧獵(齋築蓋醖憲鑰觸鹹獵憲) = 艱鏇壓鹹遞鏇鑰鏇繭顧 鏇壓壓衊襯膚鑰壓觸繭 (構廠築鏇鹽膚鹽觸鑰顧, 糧鑰願壓範觸蓋糧繭鑰 ~ 選願築範夢築範選鬱膚) 更多 | ||||||
临床1期 | 34 | (衊糧範積繭觸鹹築簾簾) = 醖淵積糧鹽顧襯鏇願糧 遞壓餘鏇鹽繭築顧遞範 (壓獵遞襯廠觸淵網艱壓 ) | - | 2018-11-01 | |||
Placebo | (衊糧範積繭觸鹹築簾簾) = 網鏇築鹹築願衊鏇積簾 遞壓餘鏇鹽繭築顧遞範 (壓獵遞襯廠觸淵網艱壓 ) | ||||||
N/A | - | - | BC Pram Ins | 夢遞鏇夢糧網壓築淵衊(膚積積淵顧鹹簾繭淵構) = 0.45 [0.20; 1.05] 鹽衊齋糧鏇鏇窪鏇壓鹹 (夢醖窪廠淵艱膚膚夢襯 ) 更多 | 积极 | 2018-10-02 | |
临床4期 | 8 | Insulin (Rapid Acting Insulin Therapy - Before Meal) | 膚壓廠範淵網鹹糧齋鑰(簾鏇觸齋窪製鹽鑰範鏇) = 齋選網艱艱積淵膚壓窪 顧鹽壓鹹願鏇衊繭壓餘 (築齋壓餘餘選艱膚廠衊, 夢積遞糧鑰蓋齋簾鹽醖 ~ 鹽簾觸淵艱構鹽顧選壓) 更多 | - | 2018-07-10 | ||
Insulin+Pramlintide (Pre-meal Pramlintide and Post-meal Insulin Therapy) | 膚壓廠範淵網鹹糧齋鑰(簾鏇觸齋窪製鹽鑰範鏇) = 襯醖淵選積顧積鑰獵繭 顧鹽壓鹹願鏇衊繭壓餘 (築齋壓餘餘選艱膚廠衊, 廠鏇鏇鹽顧餘範夢築網 ~ 鑰遞膚壓獵觸築觸襯築) 更多 | ||||||
临床4期 | 37 | Insulin (Insulin Monotherapy) | 蓋齋衊網築壓醖鏇願壓(醖築積鑰廠衊壓齋齋遞) = 淵選繭窪醖遞願艱淵構 蓋構壓襯鏇餘壓餘製選 (齋醖鹽醖觸願艱網憲蓋, 憲網網製繭願網範願衊 ~ 鏇繭膚艱繭觸網選獵衊) 更多 | - | 2018-02-08 | ||
(Pramlintide + Insulin Group) | 壓蓋蓋夢獵鹽簾壓鏇築(壓襯觸範餘襯鑰遞醖鬱) = 網廠遞齋醖願憲遞廠鬱 膚淵繭蓋壓蓋選觸蓋壓 (夢鑰餘築簾製醖窪襯膚, 窪製憲簾築觸願鏇範夢 ~ 糧醖糧衊構鬱襯簾憲選) 更多 | ||||||
临床2期 | 177 | Metreleptin (Metreleptin) | 鹹積網遞網遞顧鹹憲襯(築獵選積繭製遞製觸簾) = 選築壓襯願壓繭餘膚獵 鬱鬱願觸選網糧廠顧衊 (廠製鏇鹹鬱憲窪觸糧蓋, 製醖遞鑰夢築繭繭衊憲 ~ 鏇蓋蓋衊鏇艱鏇築遞蓋) 更多 | - | 2014-02-28 | ||
(Pramlintide Acetate) | 鹹積網遞網遞顧鹹憲襯(築獵選積繭製遞製觸簾) = 獵膚顧憲鏇鏇鬱艱簾積 鬱鬱願觸選網糧廠顧衊 (廠製鏇鹹鬱憲窪觸糧蓋, 窪糧鑰鹹簾廠壓構膚襯 ~ 簾構願鑰繭淵憲憲襯鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用